MR
MREO.O
—
NASDAQ
Advanced Medical Equipment & Technology
Mereo BioPharma Group PLC
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
51,1M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
-8 021,4 %
ROE
-102,4 %
Net margin
-8 375,6 %
Debt / equity
0,00
Beta
—
52w range
—
Volume
26,7k
Day range
$0,31–$0,34
Prev close
$0,33
Open
$0,31
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Mereo BioPharma Group PLC is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with rare and autoimmune diseases.
Business. Mereo BioPharma Group PLC (MREO.O) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm is headquartered in the United Kingdom and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
BUY8 analysts
5 buy3 hold0 sell
Avg 12m price target1,75
Analyst recommendations
8 analysts · consensus BuyBuy5
Hold3
Sell0
12-month price target
1,75
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
8 analysts · indicative
Ownership→
UBS Financial Services, Inc.
largest disclosed fund holder
Profitability→
-102,4 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to MREO.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Mereo BioPharma Group PLC (MREO.O) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm is headquartered in the United Kingdom and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupAdvanced Medical Equipment & Technology
AI synthesis
GENERATEDMereo BioPharma Group PLC maintains a strong liquidity position, with cash and equivalents amounting to $40.99 million, representing 90% of its total assets. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure. The current ratio of 10.46 suggests a robust ability to meet short-term obligations.
The company is currently unprofitable, with a net loss of $41.88 million and an operating loss of $40.11 million. Its return on equity (ROE) is -1.02, and return on assets (ROA) is -0.91, both significantly below the industry median for biotechnology firms. Gross profit of $36.7 million is offset by high R&D and operating expenses, which is typical for early-stage biopharma companies.
Geographically, Mereo BioPharma's revenue is concentrated in a few key markets, with the United Kingdom and the United States representing the majority of its disclosed revenue. The company has no material revenue from emerging markets, which limits its exposure to high-growth regions.
The company's revenue is expected to remain flat in the current fiscal year, with no significant growth anticipated in the next fiscal year. This is consistent with its current focus on late-stage clinical trials rather than commercial product sales. Free cash flow is negative at -$41.53 million, driven by high R&D and operating expenses.
Risk factors include the high probability of continued losses and the need for additional capital to fund operations. The company has no immediate filing-based liquidity or dilution flags, and its dilution potential is currently low. However, the absence of long-term debt and strong cash reserves provide a buffer against short-term financial stress.
Recent events include the initiation of a Phase III trial for its lead candidate, which could represent a material inflection point for the company. No recent regulatory or legal issues have been disclosed, and the company's risk assessment remains stable.
Key takeaways
- Mereo BioPharma Group PLC has a strong liquidity position with no long-term debt and a current ratio of 10.46.
- The company is currently unprofitable, with a net loss of $41.88 million and ROE of -1.02.
- Revenue is concentrated in the United Kingdom and the United States, with no material exposure to emerging markets.
- The company is expected to remain flat in revenue for the current and next fiscal years.
- No immediate liquidity or dilution risks are present, but continued losses may require additional capital in the future.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$0,32
Market cap
$37.7M
Enterprise valueⓘ
-$3.3M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
0.9x
P / Tangible bookⓘ
0.9x
Tangible book
$40.9M
Net cashⓘ
$41.0M
Current ratioⓘ
10.5
Debt / equityⓘ
0.0
ROAⓘ
-91.2%
ROEⓘ
-1.0%
Cash conversionⓘ
74.0%
CapEx / revenueⓘ
-64.0%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships3 disclosed relationships · 2 types · extracted from filings & disclosures
Partners1
Ultragenyx Pharmaceutical InRARE.OPartner98%Source ↗
Vendors2
ASTRAZENECA PLCAZN.LVendor90%Source ↗
NOVARTIS AGNVS.OVendor90%Source ↗
Supply chain
Vendors → MREO ↔ Partners → Customers · click any node to drill
3 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
Peer comparison8 peers · vs MREO · multiples and returns
TM
TMO—
Thermo Fisher Scientific Inc
$574,03
214,1B USDP/E
29,4x
— vs self
Div yield
0,3 %
— vs self
ROE
12,9 %
+115,3 vs self
DH
DHR—
Danaher Corp
$197,50
140,1B USDP/E
38,2x
— vs self
Div yield
—
— vs self
ROE
6,9 %
+109,2 vs self
GE
GEHC—
GE HEALTHCARE TECHNOLOGIES INC.
$69,72
31,9B USDP/E
13,6x
— vs self
Div yield
0,2 %
— vs self
ROE
19,5 %
+121,9 vs self
PH
PHG—
PHG
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BS
BSX—
Boston Scientific Corp
$48,54
72,6B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
IS
ISRG—
INTUITIVE SURGICAL, INC.
$376,00
133,2B USDP/E
287,7x
— vs self
Div yield
—
— vs self
ROE
3,6 %
+105,9 vs self
A
A—
Agilent Technologies Inc
$139,80
39,6B USDP/E
29,0x
— vs self
Div yield
0,8 %
— vs self
ROE
19,3 %
+121,7 vs self
EW
EW—
Edwards Lifesciences Corp
$88,82
51,6B USDP/E
44,3x
— vs self
Div yield
—
— vs self
ROE
10,4 %
+112,7 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-0,03
Predicted surprise
+0,00
Beat probability
45 %
Analysts
8
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-15 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,03 |
| Revenue | —no estimate | —no estimate | 32,4M USD |
| Operating income | —no estimate | —no estimate | -18,6M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution8 analysts
Strong buy3
Buy2
Hold3
Sell0
Strong sell0
12-month price target$1,75 · Median $1,50
Low $0,50High $3,00
Operating income · consensus-18,6M USD
EPS surprise
−66,7 %
reported vs consensus · miss
Revenue surprise
−98,5 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$0,50
Mean$1,75
Median$1,50
High$3,00
Spot$0,32
+446.9 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-8 021,4 %Bottom quartile
Net Margin-8 375,6 %Bottom quartile
ROE-102,4 %Bottom quartile
Capex / Rev-64,0 %Bottom quartile
D/E0,00Above median
Cash Conv0,74Below median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 5 233 665 sh29 grants13 insiders
- Director · Deferred Restricted Stock Units → American Depository SharesAcquired 96 163grant · 2026-02-26
- Director · Share Options (Right to buy) → American Depositary SharesAcquired 66 000 @ $0,39grant · 2026-02-26
- Director · Deferred Restricted Stock Units → American Depository SharesAcquired 133 560grant · 2026-02-26
- Director · Share Options (Right to buy) → American Depositary SharesAcquired 66 000 @ $0,39grant · 2026-02-26
- Director · Deferred Restricted Stock Units → American Depository SharesAcquired 117 533grant · 2026-02-26
- Director · Share Options (Right to buy) → American Depositary SharesAcquired 66 000 @ $0,39grant · 2026-02-26
- Director · Share Options (Right to buy) → American Depositary SharesAcquired 66 000 @ $0,39grant · 2026-02-26
- Director · Deferred Restricted Stock Units → American Depository SharesAcquired 106 848grant · 2026-02-26
- Director · Share Options (Right to buy) → American Depositary SharesAcquired 66 000 @ $0,39grant · 2026-02-26
- Director · Share Options (Right to buy) → American Depositary SharesAcquired 66 000 @ $0,39grant · 2026-02-26
- Director · Deferred Restricted Stock Units → American Depository SharesAcquired 96 163grant · 2026-02-26
- Director · Share Options (Right to buy) → American Depositary SharesAcquired 66 000 @ $0,39grant · 2026-02-26
- Director · Deferred Restricted Stock Units → American Depository SharesAcquired 106 848grant · 2026-02-26
- Director · Share Options (Right to buy) → American Depositary SharesAcquired 66 000 @ $0,39grant · 2026-02-26
- Chief Scientific Officer · Share Options (Right to buy) → American Depositary SharesAcquired 139 913 @ $0,44grant · 2026-02-01
- Chief Financial Officer · Share Options (Right to buy) → American Depositary SharesAcquired 315 750 @ $0,44grant · 2026-02-01
- Chief Scientific Officer · Share Options (Right to buy) → American Depository SharesAcquired 145 000 @ $0,44grant · 2026-02-01
- Chief Scientific Officer · Share Options (Right to buy) → American Depository SharesAcquired 46 637 @ $1,00grant · 2026-02-01
- General Counsel · Share Options (Right to buy) → American Depository SharesAcquired 295 000 @ $0,44grant · 2026-02-01
- General Counsel · Share Options (Right to buy) → American Depository SharesAcquired 105 250 @ $1,00grant · 2026-02-01
- General Counsel · Share Options (Right to buy) → American Depositary SharesAcquired 315 750 @ $0,44grant · 2026-02-01
- See Remarks · Share Options (Right to buy) → American Depository SharesAcquired 195 000 @ $0,44grant · 2026-02-01
- See Remarks · Share Options (Right to buy) → American Depository SharesAcquired 61 250 @ $1,00grant · 2026-02-01
- See Remarks · Share Options (Right to buy) → American Depositary SharesAcquired 183 750 @ $0,44grant · 2026-02-01
- Director, Chief Executive Officer · Share Options (Right to buy) → American Depositary SharesAcquired 1 035 000 @ $0,44grant · 2026-02-01
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
Source documents
- Mereo BioPharma Group PLC Market data — financials · 2026-05-28
- Mereo BioPharma Group PLC Market data — analyst estimates · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
Insider activity
— missing data
Short positioning
3.5Mshares short-39.9% vs prior
3.23days to cover
26.5%short of daily vol
810fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
MREO.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorPartnersVendors
Evidence & claims
From filings & derived data- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -32.9%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -15.1%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 15.3%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 5.7%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -3.2%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 16.7%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 16.7%Derived (calculated)
- Return on assets (FY 2025-12-31): 91.2%Derived (calculated)
- Return on equity (FY 2025-12-31): 102.4%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -41.3%Derived (calculated)
- Current ratio (FY 2025-12-31): 10.46xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.12xDerived (calculated)
- Net margin (FY 2025-12-31): 8,375.6%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -67.6%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -39.9%Derived (calculated)
- Operating cash flow (annual): USD -30.97MSEC XBRL filing
- Current assets (annual): USD 45.02MSEC XBRL filing
- Current liabilities (annual): USD 4.3MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
- Net income (annual): USD 41.88MSEC XBRL filing
- Capex (annual): USD 20KSEC XBRL filing
- Operating income (annual): USD -40.11MSEC XBRL filing
- Cash & equivalents (annual): USD 40.99MSEC XBRL filing
- Shareholders' equity (annual): USD 40.92MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-29 22:34 UTCEVENTHa Price Listing MREO remains DEFICIENT (NASDAQ) — cure period. closed below $1.00 for 115 consecutive trading days (last close $0.3038). cure deadline 2027-01-17 (172 days remaining).
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-02-26 00:00 UTCINSIDER29 insider transactions — 2026-02 29 derivative
2026-02-26INSIDERShames Daniel acquired 96.2k sh Deferred Restricted Stock Units — Director
2026-02-26INSIDERJacquet Pierre acquired 106.8k sh Deferred Restricted Stock Units — Director
2026-02-26INSIDERYoskowitz Marc J acquired 66.0k sh Share Options (Right to buy) — Director
2026-02-26INSIDERJacquet Pierre acquired 66.0k sh Share Options (Right to buy) — Director
2026-02-26INSIDEREkblom Anders acquired 133.6k sh Deferred Restricted Stock Units — Director
2026-02-26INSIDERBender Jeremy acquired 117.5k sh Deferred Restricted Stock Units — Director
2026-02-26INSIDERPAKIANATHAN DEEPIKA acquired 66.0k sh Share Options (Right to buy) — Director
2026-02-26INSIDERJenkins Annalisa acquired 66.0k sh Share Options (Right to buy) — Director
2026-02-26INSIDERJenkins Annalisa acquired 106.8k sh Deferred Restricted Stock Units — Director
2026-02-26INSIDERWYZGA MICHAEL S acquired 66.0k sh Share Options (Right to buy) — Director
2026-02-26INSIDERShames Daniel acquired 66.0k sh Share Options (Right to buy) — Director
2026-02-26INSIDEREkblom Anders acquired 66.0k sh Share Options (Right to buy) — Director
2026-02-26INSIDERBender Jeremy acquired 66.0k sh Share Options (Right to buy) — Director
2026-02-26INSIDERYoskowitz Marc J acquired 96.2k sh Deferred Restricted Stock Units — Director
2026-02-01INSIDERLewicki John A. acquired 139.9k sh Share Options (Right to buy) — Chief Scientific Officer
2026-02-01INSIDERScots-Knight Denise acquired 480.0k sh Share Options (Right to buy) — Director, Chief Executive Officer
2026-02-01INSIDERFox Christine Ann acquired 280.0k sh Share Options (Right to buy) — Chief Financial Officer
2026-02-01INSIDERSermon Charles acquired 315.8k sh Share Options (Right to buy) — General Counsel
2026-02-01INSIDERHughes-Wilson Alexandra acquired 195.0k sh Share Options (Right to buy) — See Remarks
2026-02-01INSIDERSermon Charles acquired 105.2k sh Share Options (Right to buy) — General Counsel
2026-02-01INSIDERHughes-Wilson Alexandra acquired 61.2k sh Share Options (Right to buy) — See Remarks
2026-02-01INSIDERHughes-Wilson Alexandra acquired 183.8k sh Share Options (Right to buy) — See Remarks
Showing the 40 most recent of 49 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage